# GPT 5.2 Review - Reviewer 1/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-23T22:11:27.055894
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0c77b98bd8cb743d006973e357e3d8819487321d181c98d947
**Tokens:** 9734 in / 6235 out
**Response SHA256:** 0f3f76d585aa6b6b

---

## 1. FORMAT CHECK

**Length (≥25 pages?)**  
- **Fails top-journal norm.** The provided manuscript appears to be **~19 pages including figures and appendix** (page numbers run at least through 19). Excluding references/appendix, the main text looks closer to **~16–17 pages**. For AER/QJE/JPE/ReStud/Ecta/AEJ:EP, this is typically **too short**, especially given the ambition (“credibly evaluating crisis-response policies”) and the need for extensive robustness/diagnostics.

**References (coverage of relevant literature?)**  
- **Insufficient for top journal.** You cite Buchmueller & Carey (2018), Patrick et al. (2016), Mallatt (2019), Kaestner & Ziedan (2019), and core DiD method papers Goodman-Bacon (2021), Sun & Abraham (2021).  
- Major omissions: modern DiD estimators/diagnostics (Callaway–Sant’Anna; de Chaisemartin–D’Haultfoeuille; Borusyak–Jaravel–Spiess; Roth; Rambachan–Roth) and key opioid-policy substitution literature (e.g., Alpert–Powell–Pacula; Evans–Lieber–Power; others). See Section 4 below.

**Prose: paragraphs vs bullets**  
- **Pass.** Major sections (Introduction, Data, Empirical Strategy, Results, Discussion) are written in paragraphs. Some enumerations appear in Discussion (p. 15–16) but not in a way that replaces prose.

**Section depth (3+ substantive paragraphs each?)**  
- **Borderline.**  
  - Introduction (p. 2–3): ~3+ paragraphs → OK.  
  - Data (p. 3–7): multiple paragraphs → OK.  
  - Empirical strategy (p. 8–9): short but ~3 subsections → OK.  
  - Results (p. 10–15): multiple subsections but some are thin (e.g., robustness is very brief).  
  - Discussion/Conclusion (p. 15–16): present but **too compressed** for a top outlet given identification concerns.

**Figures (visible data, axes, labels?)**  
- **Mostly pass.**  
  - Event study figure shows points, confidence band, axes, and event time labels (p. 12–13).  
  - Map figure has a legend; but for publication-quality, ensure **readable labels**, explicit statement of **which states are excluded/missing** directly on the figure, and a scale note if relevant.

**Tables (real numbers?)**  
- **Pass.** Tables 1–3 show actual summary stats and estimates with standard errors. Appendix table provides dates.

---

## 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard errors
- **Pass.** Main coefficients in Table 3 have SEs in parentheses (p. 10–11). Event-study coefficients are reported with SEs/p-values in text (p. 12).

### b) Significance testing
- **Pass.** You report p-values (abstract; results text) and SEs; table notes include star thresholds.

### c) Confidence intervals (95% CI)
- **Borderline / effectively missing in tables.**  
  - You show 95% CI visually in Figure 1, but **main tables do not report 95% CIs**. A top journal would expect CIs for headline estimates (TWFE and heterogeneity-robust ATT), especially given your theme is **imprecision**.
  - Add explicit 95% CIs in Table 3 and in the abstract. Example: TWFE 0.020 (SE 0.058) ⇒ ~[−0.094, 0.134] in logs.

### d) Sample sizes
- **Pass (partially).** You report N and jurisdictions for both TWFE and Sun–Abraham in Table 3, and you are transparent about missingness/singletons (p. 4–5, p. 10–11).  
- However, the event study should clearly report **how many cohorts contribute to each event time** (a standard “N cohorts / N states” by k). This matters because your pre-trend rejection at **t = −3** (p. 12) might be driven by a small subset of cohorts.

### e) DiD with staggered adoption
- **Partial pass; not enough for top journal as executed.**
  - You correctly flag TWFE hazards and implement Sun–Abraham (p. 8–9). That avoids the most obvious “already-treated as controls” contamination in event studies.
  - But you **do not implement** other modern estimators that are now standard in top-journal empirical work (Callaway–Sant’Anna; de Chaisemartin–D’Haultfoeuille; Borusyak–Jaravel–Spiess/imputation). Given the severe design constraints (limited pre-period; strong selection), showing that conclusions are robust across estimators is essential.

### f) RDD
- Not applicable (you do not use RDD).

**Bottom line on methodology:** statistical inference is present, but the paper is **not publishable in its current form** for a top general-interest journal because (i) the central identifying assumption is visibly violated (Section 3 below), and (ii) the design choices (annualization; log(count+1); treatment coding; control contamination) create avoidable attenuation and bias that you have not resolved.

---

## 3. IDENTIFICATION STRATEGY

### Credibility
- **Currently weak.** Your own event study shows a statistically significant pre-trend at **t = −3 (p = 0.007)** (p. 12), which is a direct warning that parallel trends fails for your main identifying comparison set (later adopters vs never-treated). In top outlets, an event-study pre-trend rejection at conventional levels typically triggers either:
  1) a redesigned identification strategy, or  
  2) a formal sensitivity/bounding exercise (e.g., Rambachan–Roth), plus compelling evidence that the violation is not economically meaningful.

### Key assumptions and discussion
- You discuss parallel trends and endogeneity concerns (p. 12; p. 15–16). This transparency is commendable, but **transparency is not identification**. The paper’s headline claim becomes: “we cannot estimate this credibly with these data.” That is not a sufficient contribution for AER/QJE/JPE/ReStud/Ecta/AEJ:EP unless paired with a novel solution or dataset.

### Placebos and robustness
- **Insufficient and not targeted to the core threats.**  
  - A single robustness check using opioid share of overdoses (p. 15) does not address: selection into adoption; heterogeneous effects by opioid type (prescription vs fentanyl/heroin); and timing mismeasurement.
  - You need: (i) alternative outcome definitions by opioid category; (ii) sensitivity to timing (monthly/quarterly); (iii) alternative control groups; (iv) state-specific trends or pre-period matching (careful: can introduce bias, but at least informative); and (v) formal pre-trend sensitivity.

### Do conclusions follow from evidence?
- You mostly refrain from overclaiming and emphasize limitations (p. 15–16). That said, even the “null” framing is potentially misleading: with your SEs, the data are consistent with **material harms or benefits**; and with violated pre-trends, even the sign is hard to interpret.

### Limitations discussed?
- Yes (p. 15–16): short pre-period, annual coding, lack of prescribing data, substitution. This is good—but again, in a top journal, the paper must **overcome** limitations, not just list them.

---

## 4. LITERATURE (MISSING REFERENCES + BibTeX)

### Missing DiD methodology (must cite and ideally implement/benchmark)
1) **Callaway & Sant’Anna (group-time ATT estimator)** — standard alternative to TWFE in staggered adoption.  
```bibtex
@article{CallawaySantanna2021,
  author  = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title   = {Difference-in-Differences with Multiple Time Periods},
  journal = {Econometrica},
  year    = {2021},
  volume  = {89},
  number  = {1},
  pages   = {325--360}
}
```

2) **de Chaisemartin & D’Haultfoeuille (TWFE bias under heterogeneity; alternative estimators)**  
```bibtex
@article{DeChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

3) **Borusyak, Jaravel & Spiess (imputation / efficient event-study under staggered adoption)** — important benchmark given your limited pre-period and missingness.  
```bibtex
@techreport{BorusyakJaravelSpiess2021,
  author      = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title       = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  institution = {NBER},
  year        = {2021},
  number      = {28252}
}
```

4) **Roth (pre-trend tests; power; interpretation)** — particularly relevant since you reject pre-trends at t = −3.  
```bibtex
@techreport{Roth2022Pretrends,
  author      = {Roth, Jonathan},
  title       = {Pretest with Imperfect Pre-Trends},
  institution = {NBER},
  year        = {2022},
  number      = {30391}
}
```

5) **Rambachan & Roth (formal sensitivity to pre-trend violations)** — essential given your pre-trend rejection.  
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Quarterly Journal of Economics},
  year    = {2023},
  volume  = {138},
  number  = {2},
  pages   = {255--309}
}
```

6) **Abadie (synthetic controls overview)** — relevant because you suggest SC as future work (p. 16) but do not engage the literature.  
```bibtex
@article{Abadie2021,
  author  = {Abadie, Alberto},
  title   = {Using Synthetic Controls: Feasibility, Data Requirements, and Methodological Aspects},
  journal = {Journal of Economic Literature},
  year    = {2021},
  volume  = {59},
  number  = {2},
  pages   = {391--425}
}
```

### Missing opioid-policy economics literature (substitution and mechanisms)
Your discussion mentions substitution to illicit opioids but does not cite foundational empirical work documenting substitution dynamics in the opioid crisis.

7) **Alpert, Powell & Pacula (supply-side restrictions + substitution)**  
```bibtex
@article{AlpertPowellPacula2018,
  author  = {Alpert, Abby and Powell, David and Pacula, Rosalie Liccardo},
  title   = {Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids},
  journal = {American Economic Journal: Economic Policy},
  year    = {2018},
  volume  = {10},
  number  = {4},
  pages   = {1--35}
}
```

8) **Evans, Lieber & Power (OxyContin reformulation; heroin/fentanyl substitution)**  
```bibtex
@article{EvansLieberPower2019,
  author  = {Evans, William N. and Lieber, Ethan M. J. and Power, Patrick},
  title   = {How the Reformulation of OxyContin Ignited the Heroin Epidemic},
  journal = {Review of Economics and Statistics},
  year    = {2019},
  volume  = {101},
  number  = {1},
  pages   = {1--15}
}
```

(You should also more comprehensively cover the PDMP empirical literature beyond the few cited studies—there is substantial work on PDMP mandates, utilization, doctor shopping, and mortality; top journals will expect a systematic accounting of why your design adds value relative to existing quasi-experimental evidence.)

---

## 5. WRITING QUALITY (CRITICAL)

### a) Prose vs bullets
- **Pass.** The manuscript is written in paragraphs. However, the **paper reads like a careful replication-style note** rather than a top-journal narrative with a distinctive contribution.

### b) Narrative flow
- The Introduction (p. 2–3) motivates the crisis and policy response clearly.  
- The “hook” and contribution are underpowered for a top outlet: “methodological transparency” + “null/insignificant estimates” is not, by itself, a compelling central value-add unless you (i) adjudicate why prior positive findings differ, or (ii) provide a new design/data that changes conclusions.

### c) Sentence quality
- Generally clear, but often procedural (“we restrict,” “we exclude,” “we code”), with limited economic interpretation. Top outlets want sharper framing: what is the causal estimand of policy interest (prescription-opioid deaths vs total opioid deaths), what mechanisms, and what is learned even under imprecision?

### d) Accessibility / intuition
- You explain staggered-adoption issues and why Sun–Abraham is used (p. 8–9). Good.  
- But you do not provide enough intuition for **why opioid mortality (all opioids including fentanyl) is the right outcome** for PDMP mandates, given the well-known shift from prescription opioids to illicit fentanyl. A non-specialist reader will question whether you are testing the policy on the margin it plausibly affects.

### e) Figures/tables publication quality
- Close, but not there. Improve: consistent fonts, larger text, clearer legends, and (crucially) add cohort-by-event-time support counts.

---

## 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS PUBLISHABLE)

### A. Fix outcome definition to match mechanism (most important)
PDMP mandatory query plausibly reduces **prescription opioid availability**; it may have limited effect on fentanyl-driven mortality and could even increase it via substitution. Your aggregated “opioid deaths” outcome (T40.0–T40.4, T40.6) is too blunt.

Minimum set of outcomes:
1) **Prescription-type opioid deaths** (natural/semi-synthetic, methadone; potentially excluding heroin/synthetic fentanyl)  
2) **Heroin deaths**  
3) **Synthetic opioids (fentanyl) deaths**  
4) **All opioid deaths** (for comparison)  
If PDMP reduces (1) but increases (2)/(3), the net could be ~0—your current design cannot interpret this.

### B. Stop annualizing; use monthly (or at least quarterly) data
You explicitly note mid-year effective dates and attenuation (p. 16). This is not a minor caveat; it is a design flaw that mechanically biases toward zero. Since VSRR is monthly, use it.

- Define treatment at the **month** level; estimate dynamic effects with monthly event time.  
- Alternatively, if you insist on annual, use **fraction-treated exposure** in first year (share of months treated), or drop partial adoption years.

### C. Improve inference with few clusters and strong serial correlation
With ~41 jurisdictions (and only 27 in Sun–Abraham), conventional cluster-robust SEs can be unreliable. Use:
- **wild cluster bootstrap** p-values (Cameron, Gelbach & Miller style) for headline coefficients;  
- show robustness to alternative clustering (e.g., by census region×year shocks is not clustering, but you can add region×year fixed effects as a stress test).

### D. Benchmark across modern DiD estimators
Given the design fragility, you need a “table of estimators”:
- TWFE (acknowledged problematic, but shown)
- Sun–Abraham (already)
- **Callaway–Sant’Anna**
- **de Chaisemartin–D’Haultfoeuille**
- **Borusyak–Jaravel–Spiess imputation**
If conclusions vary, explain why; if consistent, credibility improves.

### E. Address the pre-trend failure formally
Right now, the event study undermines the design (p. 12). Options:
- Implement **Rambachan–Roth** sensitivity: how large must deviations from parallel trends be to flip conclusions?  
- Show pre-trends separately by cohort and by baseline mortality levels.  
- Try a matched DiD design (carefully): match later adopters to never-treated on pre-2015 levels/trends using external mortality data (see next point).

### F. Extend pre-period using different mortality data (key for salvage)
You claim mortality data “begin in 2015” (p. 1, p. 4), but opioid overdose death counts exist historically in CDC WONDER / NVSS (final data), albeit with different formatting and possibly suppression issues. For a publishable design:
- Build a longer pre-period (e.g., **2005–2014**) using final NVSS/WONDER state-year mortality rates.  
- Use VSRR only for later years if needed, but harmonize definitions.  
Without a longer pre-period, you are structurally unable to evaluate early adopters and you have limited leverage to test trends.

### G. Clarify and stress-test “never-treated” classification
You code MI, CA, etc. as never-treated due to exemptions (Appendix A1; p. 6). That is defensible under a “comprehensive mandate” definition, but it creates **control-group contamination risk** because these places likely had partial mandates or other PDMP intensification. You should:
- Provide alternative codings (broad vs narrow mandate)  
- Show robustness excluding “borderline never-treated” (MI, CA) from the control group  
- Consider a treatment intensity index rather than a binary.

### H. Use per-capita rates / appropriate count models
You use log(count+1) (Table 3). For mortality, per-capita rates are standard:
- outcome = log(deaths per 100k + small constant), or  
- Poisson pseudo-ML with **log(population)** offset and FE (and cluster-robust SEs).  
At minimum, show robustness to population scaling; otherwise large states dominate count variation.

---

## 7. OVERALL ASSESSMENT

### Key strengths
- **Transparency** about sample construction, missing data, always-treated cohorts, and estimator limitations (p. 4–5; p. 10–12; p. 15–16).  
- Correct recognition of staggered adoption issues; Sun–Abraham implementation is a step in the right direction (p. 8–9).  
- Clear exposition and generally readable tables/figures.

### Critical weaknesses (fatal for top journals as-is)
1) **Identification is not credible**: you find a strong **pre-trend violation** (t = −3, p = 0.007; p. 12), and you do not provide a design-based solution or formal sensitivity analysis.  
2) **Outcome too aggregated** relative to PDMP mechanism; you risk concluding “no effect” while masking offsetting effects across opioid types.  
3) **Annual treatment coding with mid-year implementation** mechanically attenuates effects (p. 16).  
4) **Contribution is currently negative/diagnostic** (“hard to evaluate”), but without a new design/data that overcomes the challenge, this is unlikely to clear the bar at AER/QJE/JPE/ReStud/Ecta/AEJ:EP.  
5) Literature positioning is incomplete; key modern DiD and opioid substitution literatures are missing.

### Specific improvements needed
- Move to monthly (or fraction-treated) timing; decompose outcomes by opioid type; extend pre-period using NVSS/WONDER; benchmark multiple DiD estimators; add formal sensitivity to pre-trend violations; strengthen inference (wild bootstrap); and rethink the control group classification.

DECISION: REJECT AND RESUBMIT